Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Lung Diseases, Interstitial » Pulmonary Fibrosis
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Fibrosis » Pulmonary Fibrosis
Description
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death. MeSH
Hierarchy View
Subtype Terms (1)
Idiopathic Pulmonary Fibrosis
164 drugs (61 approved, 103 experimental)
Phase 4 Indicated Drugs (1)
Phase 1 Indicated Drugs (13)
Other Experimental Indicated Drugs (2)
Organization Involved with Phase 4 Indications (15)
Organization Involved with Phase 3 Indications (54)
Assistance Publique - Hôpitaux de Paris
Canadian Cystic Fibrosis Foundation
Interstitial Lung Disease Study Group, Korea
Katholieke Universiteit Leuven
Medical University of South Carolina
Organization Involved with Phase 2 Indications (107)
Beijing Kawin Technology Share-Holding Co., Ltd.
Bharat Biotech International Limited
Bombay Hospital & Medical Research Center
Chinese Academy of Medical Sciences
Coalition for Pulmonary Fibrosis
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Cystic Fibrosis Foundation Therapeutics
Daw Park Repatriation, Australia
Dunedin Public Hospital, New Zealand
Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
Global Blood Therapeutics, Inc.
Huazhong University of Science and Technology
Hubei University of Chinese Medicine
Institut National de la Santé Et de la Recherche Médicale, France
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Jingmen No.1 People’s Hospital
Life Mount Edgecombe Hospital, South Africa
National Human Genome Research Institute (NHGRI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
P.D. Hinduja Hospital and Medical Research Centre, Mumbai
Pulmonary Research of Abingdon, LLC
Rajiv Gandhi University of Health Sciences
Shanghai University of Traditional Chinese Medicine
Sri Bala Medical Centre and Hospital, India
Organization Involved with Phase 1 Indications (42)
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Institute of Oncology Dr. Rosell (IOR)
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Organization Involved with Other Experimental Indications (20)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.